Document and Entity Information - USD ($) |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2024 |
Feb. 25, 2025 |
Jun. 30, 2024 |
|
| Cover [Abstract] | |||
| Entity Registrant Name | FATE THERAPEUTICS, INC. | ||
| Entity Central Index Key | 0001434316 | ||
| Document Type | 10-K | ||
| Document Period End Date | Dec. 31, 2024 | ||
| Amendment Flag | false | ||
| Current Fiscal Year End Date | --12-31 | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Voluntary Filers | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Interactive Data Current | Yes | ||
| Entity Shell Company | false | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | false | ||
| Trading Symbol | FATE | ||
| Title of 12(b) Security | Common Stock, $0.001 par value | ||
| Security Exchange Name | NASDAQ | ||
| Document Annual Report | true | ||
| Document Transition Report | false | ||
| ICFR Auditor Attestation Flag | false | ||
| Document Financial Statement Error Correction Flag | false | ||
| Entity Public Float | $ 369,000,000 | ||
| Entity Common Stock, Shares Outstanding | 114,597,425 | ||
| Document Fiscal Year Focus | 2024 | ||
| Document Fiscal Period Focus | FY | ||
| Entity Tax Identification Number | 65-1311552 | ||
| Entity File Number | 001-36076 | ||
| Entity Incorporation, State or Country Code | DE | ||
| Entity Address, Address Line One | 12278 Scripps Summit Drive | ||
| Entity Address, City or Town | San Diego | ||
| Entity Address, State or Province | CA | ||
| Entity Address, Postal Zip Code | 92131 | ||
| City Area Code | 858 | ||
| Local Phone Number | 875-1800 | ||
| Documents Incorporated by Reference | Portions of the registrant’s definitive proxy statement to be filed with the Securities and Exchange Commission, or SEC, on or before the date 120 days after the conclusion of the registrant’s fiscal year ended December 31, 2024 pursuant to Regulation 14A, in connection with the registrant’s 2025 Annual Meeting of Stockholders are incorporated by reference into Part III of this annual report on Form 10-K. | ||
| Auditor Name | Ernst & Young, LLP | ||
| Auditor Location | San Diego, CA | ||
| Auditor Firm ID | 42 | ||
| Auditor Opinion | We have audited the accompanying consolidated balance sheets of Fate Therapeutics, Inc. (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders’ equity and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles. |